BOOK
Contribution of FDG to Modern Medicine, Part I, An Issue of PET Clinics, E-Book
(2014)
Additional Information
Book Details
Abstract
This issue of PET Clinics examines the Contribution of FDG to Modern Medicine. In the first of two issues, articles include: The Basic Principles of FDG-PET/CT Imaging; FDG-PET in Diffuse Large B-cell Lymphoma; FDG-PET in Thoracic Malignancies; FDG-PET/CT in Gastrointestinal Malignancies; FDG-PET/CT in Infectious and Inflammatory Diseases; FDG in Urologic Malignancies; FDG-PET for Interventional Oncology in Liver Malignancy; FDG-PET in Neurology and Psychiatry, and more!
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Contribution of FDG toModern Medicine, Part I\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| Contents | v | ||
| Pet Clinics\r | viii | ||
| Preface\r | xi | ||
| The Basic Principles of FDG-PET/CT Imaging | 355 | ||
| Key points | 355 | ||
| Introduction | 355 | ||
| Short historical overview of the early PET evolution | 356 | ||
| Basic physics: positron emission and annihilation | 357 | ||
| PET-scanner design | 358 | ||
| Novel Developments | 360 | ||
| PET radionuclides and production of FDG | 360 | ||
| The FDG concept | 361 | ||
| Cellular Uptake of FDG | 361 | ||
| Factors Influencing FDG Uptake | 362 | ||
| Correlation Between 18F-FDG Accumulation and the Levels of GLUT, HK, HIF, and Glucose-6-Phosphatase | 362 | ||
| Patient preparation, physiologic uptake, and pitfalls | 363 | ||
| Concluding remarks | 367 | ||
| References | 368 | ||
| Fluorodeoxyglucose PET in Neurology and Psychiatry | 371 | ||
| Key points | 371 | ||
| Introduction | 371 | ||
| Imaging technique | 372 | ||
| Image Analysis and Data Acquisition | 373 | ||
| Normal anatomy | 373 | ||
| Imaging findings/pathology | 374 | ||
| Dementia | 374 | ||
| Alzheimer's disease (AD) | 374 | ||
| Frontotemporal dementia (FTD) | 377 | ||
| Dementia with lewy bodies (DLB) | 378 | ||
| Vascular dementia (VaD) | 379 | ||
| Creutzfeldt-Jakob disease (CJD) | 379 | ||
| Corticobasal Degeneration (CBD) | 381 | ||
| Epilepsy | 382 | ||
| Temporal lobe epilepsy | 382 | ||
| Extratemporal epilepsy | 383 | ||
| Schizophrenia and Bipolar Disorder | 383 | ||
| Summary | 384 | ||
| Acknowledgments | 384 | ||
| References | 384 | ||
| [18F]Fluorodeoxyglucose PET in Thoracic Malignancies | 391 | ||
| Key points | 391 | ||
| Introduction | 391 | ||
| Lung nodule characterization | 391 | ||
| Staging of non–small cell lung cancer | 394 | ||
| N Staging | 394 | ||
| M Staging | 396 | ||
| New FDG-PET Techniques for Lung Cancer Staging | 398 | ||
| Prognostication of clinical outcome in NSCLC | 398 | ||
| Dual time-point FDG-PET for evaluation of lung nodules and lung cancer | 399 | ||
| Lung Nodule Characterization | 399 | ||
| Lung Cancer Staging | 400 | ||
| Lung Cancer Tumor Biology and Patient Outcome | 400 | ||
| Radiation therapy pretreatment planning and response assessment in NSCLC | 401 | ||
| Systemic therapy response assessment in NSCLC | 402 | ||
| Restaging of NSCLC | 402 | ||
| Other specific thoracic malignancies | 403 | ||
| Small Cell Lung Cancer | 403 | ||
| Malignant Pleural Mesothelioma | 405 | ||
| Esophageal Cancer | 406 | ||
| Thymic Epithelial Tumors | 409 | ||
| Summary | 411 | ||
| References | 411 | ||
| [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies | 421 | ||
| Key points | 421 | ||
| Introduction | 421 | ||
| Gastric cancer | 422 | ||
| Introduction | 422 | ||
| Staging | 422 | ||
| Recurrence Detection | 423 | ||
| Response Evaluation, Prognosis, and Impact on Management | 424 | ||
| Summary | 424 | ||
| Pancreatic cancer | 425 | ||
| Introduction | 425 | ||
| Initial Diagnosis and Staging | 425 | ||
| Recurrence Detection | 426 | ||
| Response Evaluation, Prognosis, and Impact on Management | 426 | ||
| Summary | 427 | ||
| Primary liver malignancies | 427 | ||
| Introduction | 427 | ||
| Initial Diagnosis and Staging | 427 | ||
| Recurrence Detection | 429 | ||
| Response Evaluation, Prognosis, and Impact on Management | 429 | ||
| Summary | 430 | ||
| Colorectal malignancies and liver metastases | 430 | ||
| Introduction | 430 | ||
| Initial Diagnosis and Staging | 430 | ||
| Primary tumor and lymph node staging | 430 | ||
| Detection of liver metastases | 431 | ||
| Detection of extrahepatic metastases and impact on surgical management | 431 | ||
| Recurrence Detection | 432 | ||
| Response Assessment and Prognosis | 433 | ||
| Summary | 434 | ||
| Stroma cell tumors | 434 | ||
| Introduction | 434 | ||
| Response Assessment and Prognosis | 434 | ||
| Summary | 436 | ||
| Discussion | 436 | ||
| References | 437 | ||
| Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma | 443 | ||
| Key points | 443 | ||
| Introduction | 443 | ||
| FDG–positron emission tomography for initial staging of lymphoma | 443 | ||
| FDG–Positron Emission Tomography Versus CT | 443 | ||
| FDG-PET in Detection of Bone Marrow Involvement | 444 | ||
| FDG-PET in Detecting Extranodal Lesions and Central Nervous System Lymphoma | 446 | ||
| FDG-PET and the Use of Dual-time-point PET | 446 | ||
| FDG-PET for early response evaluation | 447 | ||
| Interpretation of Interim PET Using International Harmonization Project Criteria | 448 | ||
| Interpretation of Interim PET Using Deauville 5PS | 448 | ||
| Interpretation of Interim PET Using Quantitative Analysis | 449 | ||
| FDG-PET for posttreatment evaluation | 449 | ||
| FDG-PET for surveillance | 450 | ||
| Summary | 450 | ||
| References | 451 | ||
| FDG in Urologic Malignancies | 457 | ||
| Key points | 457 | ||
| Introduction | 457 | ||
| Frequency of urologic cancers | 457 | ||
| Kidney cancer | 458 | ||
| Preoperative Use | 459 | ||
| Metastatic Disease | 459 | ||
| Bladder cancer | 460 | ||
| Diagnosis/Staging | 460 | ||
| Prostate cancer | 462 | ||
| Primary Diagnosis | 462 | ||
| Incidental Focal Uptake | 462 | ||
| Staging | 464 | ||
| Restaging | 465 | ||
| Prognostic Value | 466 | ||
| Summary | 466 | ||
| References | 466 | ||
| [18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy | 469 | ||
| Key points | 469 | ||
| Introduction | 469 | ||
| Methods | 470 | ||
| Results | 470 | ||
| Liver Resections | 470 | ||
| Preoperative staging | 472 | ||
| Intrahepatic disease | 472 | ||
| Extrahepatic disease | 474 | ||
| Change of management | 474 | ||
| Role of FDG-PET in the follow-up | 476 | ||
| Role of FDG-PET(/CT) in hepatocellular carcinoma | 477 | ||
| Cost-effectiveness | 477 | ||
| Summary | 477 | ||
| Thermal Ablation Therapy | 478 | ||
| Preinterventional staging | 478 | ||
| Detection of residual tumor/incomplete ablation | 478 | ||
| Early detection of tumor recurrence | 482 | ||
| FDG-PET reading | 483 | ||
| Role of FDG-PET(/CT) in HCC | 483 | ||
| Cost-effectiveness analyses | 483 | ||
| Summary | 485 | ||
| Radioembolization | 485 | ||
| Preinterventional staging | 486 | ||
| Posttreatment imaging | 486 | ||
| Response assessment and prognostication | 486 | ||
| Summary | 488 | ||
| Transarterial Chemoembolization | 488 | ||
| External-Beam Radiation Therapy | 489 | ||
| Discussion | 489 | ||
| References | 490 | ||
| FDG-PET/CT in Infectious and Inflammatory Diseases | 497 | ||
| Key points | 497 | ||
| Introduction | 497 | ||
| Systemic infections | 497 | ||
| Fever and Bacteremia of Unknown Origin | 497 | ||
| Immunocompromised Patients | 498 | ||
| Infectious Endocarditis | 500 | ||
| Bone infections | 502 | ||
| Spinal Infection | 502 | ||
| Periprosthetic Joint Infections | 503 | ||
| Diabetic Foot Infection and Charcot Foot | 503 | ||
| Vascular infection and inflammation | 505 | ||
| Vascular Graft Infection | 505 | ||
| Vasculitis | 506 | ||
| Thoracic and abdominal inflammation | 507 | ||
| Sarcoidosis | 507 | ||
| Inflammatory Bowel Diseases | 509 | ||
| Potential novel applications | 510 | ||
| Psoriasis and Rheumatoid Arthritis | 510 | ||
| Chronic Obstructive Pulmonary Disease | 512 | ||
| Venous Thromboembolic Disease | 512 | ||
| Concluding remarks | 513 | ||
| References | 513 | ||
| Index | 521 |